NEWS
Degron Therapeutics won the 2023 BRACE Award Venture Competition along with the investment from Asian Fund for Cancer Research (AFCR)
Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition after thr
By Degron, December 18, 2023
Degron Therapeutics Wins the Second Prize in 2023 Women’s Venture Competition, the First Asian Company to Win in this Global Competition
Degron Therapeutics and its Co-founder and CEO, Lily Zou, Ph.D., MBA won the Second Prize in 2023 Wo
By Degron, October 18, 2023
Dr. Xiaobing Qian joins Degron Therapeutics as Chief Development Officer
Shanghai, China and San Diego, CA, February 7, 2023, Degron Therapeutics Inc. announced today that X
By Degron, Feb. 7, 2023
Degron Therapeutics Co-Founder is invited to speak at the TPD meeting in San Diego
Dr. Yong Cang, CSO and Co-Founder of Degron Therapeutics, who has dedicated his research to the TPD
By Degron, Dec. 6, 2022
Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy
Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability
By Degron, June 28, 2022,
Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
SAN DIEGO, Calif., and SHANGHAI, China, June 9, 2022 - Degron Therapeutics (“Degron”), a biotechnolo
By Degron, June 09,2022
Degron Therapeutics Had an Exclusive Interview with CCTV2 "Economy 30 Minutes" Program
At 8:00 p.m. on March 11, 2022, the prime-time program “Economy 30 Minutes” on CCTV2 broadcast a spe
By Degron, March 11, 2022
The Theme Activities of "Degron Date" Concluded Successfully
With lush greens and pleasant weather, Shanghai headed into the best March spring. Degron empoyees g
By Degron, March 10, 2022
Molecular Glue Degraders,a New Dawn Since PROTACs
Yong Cang, professor of ShanghaiTech University and co-founder of Degron Therapeutics
By Yong Cang, August 18, 2020,